MOv18 IgE
Platinum-Resistant Ovarian Cancer
Key Facts
About Epsilogen
Epsilogen is a UK-based, clinical-stage biotech positioned as the world's leading pan-isotype antibody therapeutic company for cancer. Its core innovation is developing therapeutics based on IgE and IgA antibodies, which offer distinct mechanisms of action compared to conventional IgG antibodies, including enhanced tumor access and activation of different immune effector cells. The company's lead asset, MOv18 IgE, is in a Phase Ib trial for platinum-resistant ovarian cancer, and it bolstered its IgA platform through the 2025 acquisition of TigaTx. Epsilogen represents a novel approach in the immuno-oncology landscape by expanding the antibody arsenal beyond IgG.
View full company profileAbout Epsilogen
Epsilogen is a UK-based, clinical-stage biotech positioned as the world's leading pan-isotype antibody therapeutic company for cancer. Its core innovation is developing therapeutics based on IgE and IgA antibodies, which offer distinct mechanisms of action compared to conventional IgG antibodies, including enhanced tumor access and activation of different immune effector cells. The company's lead asset, MOv18 IgE, is in a Phase Ib trial for platinum-resistant ovarian cancer, and it bolstered its IgA platform through the 2025 acquisition of TigaTx. Epsilogen represents a novel approach in the immuno-oncology landscape by expanding the antibody arsenal beyond IgG.
View full company profileTherapeutic Areas
Other Platinum-Resistant Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| ERNA-101 | Eterna Therapeutics | Preclinical |
| Upifitamab rilsodotin (UpRi) | Mersana Therapeutics | Phase 3 |
| DT2216 | Dialectic Therapeutics | Phase 1/2 |
| TTFields / INNOVATE-3 | Novocure | Phase 3 |